Veraxa Biotech Holding AG
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $169.7M
- Price
- $1.20
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.11%
- Volume
- 751.6K
About
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Quick stats
Shares outstanding141.4M
Computed float31.4M
Float / shares22.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002079109
Websitehttps://www.veraxa.com
AI Summary
AI-generated1/14
minorbullishoperations update
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
VERAXA Biotech announced it has implemented FDA-aligned New Approach Methodologies (NAMs) across all preclinical programs, positioning itself ahead of the FDA's 2025 roadmap to phase out animal testing.
New ex vivo data in ten patient-derived xenograft models of non-small cell lung cancer showed the lead BiTAC-TCE potently killed dual-target cancer cells while sparing single-target cells, using roughly ten mice versus an estimated 200 for comparable in vivo studies.
The strategy could shorten preclinical timelines and cut costs by bypassing certain non-human primate toxicology studies, supporting faster IND-enabling advancement of the BiTAC oncology pipeline.